Literature DB >> 17317851

The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.

Victoria J Christiansen1, Kenneth W Jackson, Kyung N Lee, Patrick A McKee.   

Abstract

The primary inhibitor of plasmin, alpha(2)-antiplasmin (alpha(2)AP), is secreted by the liver into plasma with Met as the amino-terminus. During circulation, Met-alpha(2)AP is cleaved by antiplasmin-cleaving enzyme (APCE), yielding Asn-alpha(2)AP, which is crosslinked into fibrin approximately 13 times faster than Met-alpha(2)AP. The Met-alpha(2)AP gene codes for either Arg or Trp as the sixth amino acid, with both polymorphic forms found in human plasma samples. We determined the Arg6Trp genotype frequency in a healthy population and its effects on Met-alpha(2)AP cleavage and fibrinolysis. Genotype frequencies were RR 62.5%, RW 34.0%, and WW 3.5%. The polymorphism related to the percentage of Met-alpha(2)AP in plasma was WW (56.4%), RW (40.6%), and RR (23.6%). WW plasma tended to have shorter lysis times than RR and RW plasmas. APCE cleaved purified Met-alpha(2)AP(Arg6) approximately 8-fold faster than Met-alpha(2)AP(Trp6), which is reflected in Asn-alpha(2)AP/Met-alpha(2)AP ratios with time in RR, RW, and WW plasmas. Removal of APCE from plasma abrogated cleavage of Met-alpha(2)AP. We conclude that the Arg6Trp polymorphism is functionally significant, as it clearly affects conversion of Met-alpha(2)AP to Asn-alpha(2)AP, and thereby, the rate of alpha(2)AP incorporation into fibrin. Therefore, the Arg6Trp polymorphism may play a significant role in governing the long-term deposition/removal of intravascular fibrin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317851      PMCID: PMC1890835          DOI: 10.1182/blood-2007-01-065185

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  The role of platelets in the initial stages of atherosclerosis.

Authors:  L Jørgensen
Journal:  J Thromb Haemost       Date:  2006-07       Impact factor: 5.824

2.  A novel missense mutation in the human plasmin inhibitor (alpha2-antiplasmin) gene associated with a bleeding tendency.

Authors:  B Lind; S Thorsen
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

3.  Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma.

Authors:  K Bangert; A H Johnsen; U Christensen; S Thorsen
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

Review 4.  The coagulation and fibrinolysis systems and atherosclerosis.

Authors:  K Tanaka; K Sueishi
Journal:  Lab Invest       Date:  1993-07       Impact factor: 5.662

5.  Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.

Authors:  T W Meade; V Ruddock; Y Stirling; R Chakrabarti; G J Miller
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

6.  A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.

Authors:  A J Jones; A M Meunier
Journal:  Thromb Haemost       Date:  1990-11-30       Impact factor: 5.249

7.  Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.

Authors:  M Levi; D Roem; A M Kamp; J P de Boer; C E Hack; J W ten Cate
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

8.  Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells.

Authors:  T Koyama; Y Koike; S Toyota; F Miyagi; N Suzuki; N Aoki
Journal:  Biochem Biophys Res Commun       Date:  1994-04-15       Impact factor: 3.575

Review 9.  The relation between atherosclerosis and thrombosis.

Authors:  J Loscalzo
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

Review 10.  On the role of coagulation and fibrinolysis in atherosclerosis.

Authors:  I Juhan-Vague; D Collen
Journal:  Ann Epidemiol       Date:  1992-07       Impact factor: 3.797

View more
  15 in total

Review 1.  α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.

Authors:  Guy L Reed; Aiilyan K Houng; Satish Singh; Dong Wang
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

2.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

3.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

4.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Authors:  Kyung N Lee; Kenneth W Jackson; Simon Terzyan; Victoria J Christiansen; Patrick A McKee
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

5.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

6.  Molecular and Physical Mechanisms of Fibrinolysis and Thrombolysis from Mathematical Modeling and Experiments.

Authors:  Brittany E Bannish; Irina N Chernysh; James P Keener; Aaron L Fogelson; John W Weisel
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

7.  Relation of α2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis.

Authors:  Berthold Hoppe; Christian Schwedler; Hildrun Haibel; Maryna Verba; Fabian Proft; Mikhail Protopopov; Hans-Gert Heuft; Valeria Rios Rodriguez; Anke Edelmann; Martin Rudwaleit; Joachim Sieper; Denis Poddubnyy
Journal:  Int J Mol Sci       Date:  2020-12-09       Impact factor: 5.923

8.  Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis.

Authors:  Berthold Hoppe; Christian Schwedler; Hildrun Haibel; Maryna Verba; Fabian Proft; Mikhail Protopopov; Hans-Gert Heuft; Valeria Rios Rodriguez; Anke Edelmann; Martin Rudwaleit; Joachim Sieper; Denis Poddubnyy
Journal:  RMD Open       Date:  2021-06

Review 9.  Inhibition of Fibrinolysis by Coagulation Factor XIII.

Authors:  Dingeman C Rijken; Shirley Uitte de Willige
Journal:  Biomed Res Int       Date:  2017-07-06       Impact factor: 3.411

10.  Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.

Authors:  Shiraazkhan Abdul; Miet Peeters; Els Brouwers; Joyce J M C Malfliet; Frank W G Leebeek; Paul J Declerck; Dingeman C Rijken; Shirley Uitte de Willige
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.